South San Francisco, Calif. — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones. “In 2022, we...
finance News
STOCKHOLM — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2023 Third Quarter 2023 Total revenue increased 29 per cent, +23 per cent at constant exchange rates, (CER)i, to SEK 5,168 M (3,999) Haematology revenue increased 25 per cent at CER to SEK 3,484 M...
WALTHAM, Mass. and WILMINGTON, Del. – Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) announced today that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody. “This partnership has the potential to significantly expand and maximize the axatilimab...
CAMBRIDGE, Mass. – As part of its commitment to reducing burdens facing the rare disease community, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced three priority policy reforms and solutions designed to address significant barriers to care for patients managing rare diseases and genetic conditions as part of a new...
MELBOURNE, Australia — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces its financial results for the financial year ended 31 December 2022. All figures are in AU$ unless otherwise stated. 2022 HIGHLIGHTS Total Group revenue $160.1M (2021: $7.6M) commercial launch of Illuccix® drives 20x increase in revenue Highly positive top-line...
TEL AVIV & WENDELSHEIM, Germany – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with...
BETHESDA, Md. – The Cystic Fibrosis Foundation affirmed its support for the PASTEUR Act, a bipartisan proposal that, if passed, will support the development of new antibiotics and promote appropriate use of existing ones. The organization issued the following statement: “New solutions are needed now to bring novel antibiotics into...
PRINCETON, N.J. – The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company. The McQuade Center for Strategic Research and Development at Otsuka in...
United States Sens. Tim Kaine (D-VA), Mark R. Warner (D-VA), Jerry Moran (R-KS) and Bill Cassidy (R-LA) introduced Thursday the Gabriella Miller Kids First Research Act 2.0, which would provide additional funding for childhood cancer research. The bill is named in honor of Gabriella Miller, a Leesburg resident who died...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. – United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2022. This award is presented by Newsweek...